Novo Nordisk Pharma Thailand introduced a higher-dose semaglutide option on October 7. The treatment addresses type 2 diabetes and linked cardiovascular risks across the country.
It targets an expanding patient base. Diabetes prevalence in Thailand climbed to 10.6 per cent in 2025, up from 9.5 per cent in the 2020 national survey.
The Danish drugmaker presented the formulation to more than 500 Thai medical practitioners at an industry gathering. The therapy targets cardiovascular-kidney-metabolic syndrome. That condition links heart disease, renal impairment, and obesity in diabetes patients.
Expanding Treatment Beyond Glycaemic Control
Cardiovascular disease is the leading cause of death among Thai type 2 diabetes patients. Chronic kidney disease also affects up to 40 per cent of diagnosed patients. Diabetes remains the primary driver of end-stage renal failure nationwide.
Doctors gain an extra clinical tool for weight management and organ protection alongside blood glucose reduction. Most Thai adults with type 2 diabetes are overweight or obese. This compounds their health risks.
Distribution runs through state hospital tenders, private hospital networks, and licensed retail pharmacies across the Kingdom. The company has operated locally for more than four decades, supplying metabolic and chronic disease therapies through all three channels.
Commercial Stakes in Southeast Asian Healthcare
Demand for advanced glucagon-like peptide-1 receptor agonists has surged across Southeast Asia. Lifestyle illnesses now place heavy pressure on state healthcare funds. In Thailand, universal health coverage schemes face rising long-term costs from dialysis and acute cardiac interventions.
Drug suppliers compete directly for formulary spots in private hospital groups and government procurement lists. Higher dosage strengths help manufacturers preserve revenue per patient. They also defend market share against emerging biosimilars and rival GLP-1 therapies entering Asian markets.
Premium chronic therapies provide healthcare operators and pharmacy chains with steady prescription volumes. Affordability and public reimbursement access remain the main hurdles. Because of those limits, high-dose therapies rely largely on private payers and self-funded patients.
Four Decades of Thai Market Presence
Novo Nordisk established its formal presence in Thailand more than 40 years ago. It built distribution relationships with public teaching hospitals and private medical groups, later rolling out baseline semaglutide formulations across Southeast Asia after global clearances.
Novo has been at the forefront of diabetes care for more than a century, and we recognise that type 2 diabetes is one of the most pressing public health challenges of our time. In Thailand, it is closely linked to CKM syndrome, conditions that place an enormous burden on families and on the Thai healthcare system.
Next year, the pharmaceutical producer will hold clinical symposiums across provincial medical hubs. These sessions will train specialists on prescribing protocols for the higher dosage.
